Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

被引：6

作者：

Grant, H. ^{[1
]}

Jiang, X. ^{[2
,3
]}

Stebbing, J. ^{[4
]}

Foroni, L. ^{[5
]}

Craddock, C. ^{[6
]}

Griffiths, M. ^{[7
]}

Clark, R. E. ^{[8
]}

O'Brien, S. ^{[9
]}

Khorashad, J. S. ^{[5
]}

Gerrard, G. ^{[5
]}

Wang, L. ^{[8
]}

Irving, J. A. E. ^{[9
]}

Wang, M. ^{[10
]}

Karran, L. ^{[11
]}

Dyer, M. J. S. ^{[11
]}

Forrest, D. ^{[12
]}

Page, K. ^{[1
]}

Eaves, C. J. ^{[2
,3
]}

Woolfson, A. ^{[13
]}

机构：

[1] UCL, Dept Math, London, England

[2] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada

[3] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada

[4] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Med Oncol, London, England

[5] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, Dept Med, London, England

[6] Queen Elizabeth Hosp, Ctr Clin Haematol, Birmingham B15 2TH, W Midlands, England

[7] Birmingham Womens NHS Fdn Trust, W Midlands Reg Genet Lab, Birmingham, W Midlands, England

[8] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England

[9] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[10] MRC, Mol Biol Lab, Div Prot & Nucle Acid Chem, Cambridge CB2 2QH, England

[11] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England

[12] British Columbia Canc Agcy, Div Hematol, Leukaemia BMT Program British Columbia, Vancouver, BC V5Z 4E6, Canada

[13] Bristol Myers Squibb Co, Discovery Med Oncol, Princeton, NJ USA

来源：

LEUKEMIA | 2010年 / 24卷 / 10期

基金：

英国医学研究理事会;

关键词：

RESISTANCE; MECHANISMS; INHIBITOR; IMATINIB;

D O I：

10.1038/leu.2010.179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1817 / 1821

页数：5

共 50 条

[31] Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia
Gado, Sarah
Hassan, Mohammed Al-Kassim
Kisla, Mehmet Murat
Ates-Alagoz, Zeynep
MEDICINAL CHEMISTRY, 2024,
[32] Detection of BCR-ABL1 tyrosine kinase domain mutations in chronic myeloidleukaemia patients with Imatinib resistance in Colombia
Vasquez Palacio, Gonzalo
Cecilia Ramirez, Gloria
Enrique Muskus, Carlos
Domingo Torres, Jose
Alberto Aya, Carlos
REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (01): : 8 - 17
[33] Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
El Missiry, Mohamed
Hjorth-Hansen, Henrik
Richter, Johan
Olson-Stromberg, Ulla
Stenke, Leif
Porkka, Kimmo
Kreutzman, Anna
Mustjoki, Satu
PLOS ONE, 2017, 12 (01):
[34] c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia
Lucas, Claire M.
Harris, Robert J.
Giannoudis, Athina
Clark, Richard E.
HAEMATOLOGICA, 2015, 100 (05)
[35] BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival
Barbosa Pagnano, Katia Borgia
Bendit, Israel
Boquimpani, Carla
De Souza, Carmino Antonio
Miranda, Eliana C. M.
Zalcberg, Ilana
Larripa, Irene
Nardinelli, Luciana
Silveira, Rosana Antunes
Fogliatto, Laura
Spector, Nelson
Funke, Vaneuza
Pasquini, Ricardo
Hungria, Vania
Chiattone, Carlos Sergio
Clementino, Nelma
Conchon, Monika
Beatriz Moiraghi, Elena
Lopez, Jose Luis
Pavlovsky, Carolina
Pavlovsky, Miguel A.
Cervera, Eduardo E.
Antonio Meillon, Luis
Simoes, Belinda
Hamerschlak, Nelson
Magarinos Bozzano, Alicia Helena
Mayta, Ernesto
Cortes, Jorge
Bengio, Raquel M.
CANCER INVESTIGATION, 2015, 33 (09) : 451 - 458
[36] Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
Katerina Machova Polakova
Vojtech Kulvait
Adela Benesova
Jana Linhartova
Hana Klamova
Monika Jaruskova
Caterina de Benedittis
Torsten Haferlach
Michele Baccarani
Giovanni Martinelli
Tomas Stopka
Thomas Ernst
Andreas Hochhaus
Alexander Kohlmann
Simona Soverini
Journal of Cancer Research and Clinical Oncology, 2015, 141 : 887 - 899
[37] Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group
Itonaga, Hidehiro
Tsushima, Hideki
Imanishi, Daisuke
Hata, Tomoko
Doi, Yuko
Mori, Sayaka
Sasaki, Daisuke
Hasegawa, Hiroo
Matsuo, Emi
Nakashima, Jun
Kato, Takeharu
Horai, Makiko
Taguchi, Masataka
Matsuo, Masatoshi
Taniguchi, Hiroaki
Makiyama, Junnya
Sato, Shinya
Horio, Kensuke
Ando, Koji
Moriwaki, Yuji
Sawayama, Yasushi
Ogawa, Daisuke
Yamasaki, Reishi
Takasaki, Yumi
Imaizumi, Yoshitaka
Taguchi, Jun
Kawaguchi, Yasuhisa
Yoshida, Shinichiro
Joh, Tatsuro
Moriuchi, Yukiyoshi
Nonaka, Hiroaki
Soda, Hisashi
Fukushima, Takuya
Nagai, Kazuhiro
Kamihira, Shimeru
Tomonaga, Masao
Yanagihara, Katsunori
Miyazaki, Yasushi
LEUKEMIA RESEARCH, 2014, 38 (01) : 76 - 83
[38] Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
Smith, Brittany M.
Brewer, Diana
Druker, Brian J.
Braun, Theodore P.
CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1707 - 1711
[39] Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
Arun, A. K.
Senthamizhselvi, A.
Mani, S.
Vinodhini, K.
Janet, N. B.
Lakshmi, K. M.
Abraham, A.
George, B.
Srivastava, A.
Srivastava, V. M.
Mathews, V.
Balasubramanian, P.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (03) : 235 - 242
[40] BCR-ABL TYROSINE KINASE DOMAIN MUTATIONS COMBINATIONS AFFECTS IMATINIB RESISTENCE IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Bintoro, S. U. Y.
Amrita, P. N. A.
Joewarini, E.
Suryohusodo, P.
Soebandiri, S.
NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 53 - 58

← 1 2 3 4 5 →